National Eye Institute; Notice of Closed Meetings, 29128 [2018-13413]
Download as PDF
<![CDATA[
29128
Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Recombinant HIV-1 Envelope Protein
for Vaccine Use
Description of Technology
In pursuit of an effective vaccine to
end the global HIV-1/AIDS pandemic,
researchers at the Vaccine Research
Center (‘‘VRC’’) continue to study the
structure of HIV-1. Recently, these
researchers have determined the threedimensional structure of the HIV-1
Envelope trimeric ectodomain (‘‘Env’’),
comprised of three gp120 and three
gp41 subunits, in its prefusion, mature,
closed conformation.
The researchers hypothesize that
immunization with the prefusion,
closed HIV-1 Env protein will elicit a
neutralizing immune response. The VRC
researchers engineered a portion of the
HIV-1 Env trimer to stabilize it in this
closed conformation for use as an
immunogen.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
trimeric pre-fusion HIV-1 Env. Nature.
2014 Oct 23; 514(7523):455–61. [PMID:
25296255].
Intellectual Property: HHS Reference
Number E–178–2014 includes U.S.
Provisional Patent Application No. 62/
046,059 filed September 4, 2014; U.S.
Provisional Patent Application No. 62/
136,480 filed March 21, 2015; PCT
Application No. PCT/US2015/048729
filed September 4, 2015; U.S. Patent
Application No. 15/508,885 filed March
3, 2017; and EPO Patent Application
No. 15766697.5 filed March 29, 2017.
Licensing Contact: Dr. Barry
Buchbinder, 240–627–3674;
barry.buchbinder@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize HIV-1 immunogens for
treating or preventing HIV-1 infection.
For collaboration opportunities, please
contact Dr. Barry Buchbinder, 240–627–
3674; barry.buchbinder@nih.gov.
Dated: June 14, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2018–13416 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
Potential Commercial Applications
• Vaccine for prevention of HIV-1
infection.
• Therapeutic vaccine for treatment
of HIV-1 infection.
Competitive Advantages
daltland on DSKBBV9HB2PROD with NOTICES
Development Stage
• In vitro studies characterizing the
immunogen and its interaction with HIV
antibodies.
• In vivo results including
immunogenicity in rabbits and guinea
pigs, neutralizing activity of resulting
serum.
Inventors: Peter D. Kwong (NIAID),
Ivelin S. Georgiev (NIAID), Michael
Gordon Joyce (NIAID), Marie L. Pancera
(NIAID), Tongqing Zhou (NIAID),
Priyamvada Acharya (NIAID), Jason J.
Gorman (NIAID), Yongping Yang
(NIAID), Aliaksandr A. Druz (NIAID),
Guillaume Stewart-Jones (NIAID), Rita
Chen (NIAID), Gwo-Yu Chuang (NIAID),
Ulrich Baxa (NIAID), John R. Mascola
(NIAID), Rebecca M. Lynch (NIAID),
Baoshan Zhang (NIAID), Cheng Cheng
(NIAID).
Publications: Pancera M., et al.
Structure and immune recognition of
17:16 Jun 21, 2018
Jkt 244001
National Institutes of Health
National Eye Institute; Notice of Closed
Meetings
• Currently, no licensed HIV-1
vaccine exists.
VerDate Sep<11>2014
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Cooperative
Agreement (UG1) and Clinical Trial Planning
Grant (R34) Applications.
Date: July 13, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Place: National Institutes of Health, 5635
Fishers Lane, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Anne E. Schaffner, Ph.D.,
Chief, Scientific Review Branch, Division of
Extramural Research, National Eye Institute,
5635 Fishers Lane, Suite 1300, MSC 9300,
Bethesda, MD 20892–9300, (301) 451–2020,
aes@nei.nih.gov.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Research
Project Grant Applications (R01).
Date: July 25, 2018.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health 5635
Fishers Lane, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Brian Hoshaw, Ph.D.,
Scientific Review Officer National Eye
Institute National Institutes of Health,
Division of Extramural Research 5635 Fishers
Lane, Suite 1300, Rockville, MD 20892, 301–
451–2020, hoshawb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–13413 Filed 6–21–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Receptor Profiling and Predictive Toxicology
(8937).
Date: July 19, 2018.
Time: 10:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
E:\FR\FM\22JNN1.SGM
22JNN1
]]>Agencies
[Federal Register Volume 83, Number 121 (Friday, June 22, 2018)]
[Notices]
[Page 29128]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13413]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Eye Institute Special Emphasis
Panel; NEI Cooperative Agreement (UG1) and Clinical Trial Planning
Grant (R34) Applications.
Date: July 13, 2018.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, 5635 Fishers Lane,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Anne E. Schaffner, Ph.D., Chief, Scientific
Review Branch, Division of Extramural Research, National Eye
Institute, 5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD
20892-9300, (301) 451-2020, [email protected].
Name of Committee: National Eye Institute Special Emphasis
Panel; NEI Research Project Grant Applications (R01).
Date: July 25, 2018.
Time: 12:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health 5635 Fishers Lane,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Brian Hoshaw, Ph.D., Scientific Review Officer
National Eye Institute National Institutes of Health, Division of
Extramural Research 5635 Fishers Lane, Suite 1300, Rockville, MD
20892, 301-451-2020, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.867,
Vision Research, National Institutes of Health, HHS)
Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-13413 Filed 6-21-18; 8:45 am]
BILLING CODE 4140-01-P
